Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Vision recovery speed after ReLEx SMILE surgery

Poster Details

First Author: E. Eskina RUSSIAN FEDERATION

Co Author(s):    V. Parshina   O. Kukleva                 

Abstract Details

Purpose:

To evaluate vision acuity speed recovery for patients underwent conventional

Setting:

Prof. Erika N. Eskina, MD, Laser Surgery Clinic SPHERE, Moscow, Russia

Methods:

There were 22 patients (44 eyes) (29±5 years, range 21 to 44) with SEQ -4.85D±2,03D (range -1,25D to -8,5D) VisuMax femtosecond laser system (CZM) with the following parameters: flap thickness 110-120 mkm, RST more than 300 mkm. Planned OZ was in average 6,28±0,6 mm (range from 5,4 to 7,2 mm), lens thickness 94± 13 mkm (range from 65 to 116 mkm). Patients were analysed at 1, 7 days and 1, 3 - months postop. Clinical outcomes were evaluated in terms of clinical refraction, BCVA, UCVA and safety.

Results:

The UCVA before the operation was 0,075±0,06, BCVA 0,98±0,06. Uncorrected vision recovery speed was estimated at 1, 7 days and 1, 3 -months postop 0,78±0,2, 0,86±0,13, 0,92±0,1 and reached 0,98±0,1 at 3 months and remained stable during further observation. Average BCVA at 3 months was the same like before the operation. There were 4 eyes (9,1%) lost 1 line from BCVA, 3 eyes (6,8%) gained 1 or more lines BCVA. 33 eyes (75%) reached target refraction, 38 eyes (86,3%) were within 0,25 D from target refraction, 43 eye (97,7%) – within 0,5 D from target.

Conclusions:

ReLex Smile is a safe and predictable method in correction myopia in a range from low to high degree. Vision recovery speed was high enough to provide a driving ability within 1 day after surgery and reached BCVA level at 1-3 months after surgery. Described data could help in explaining of vision recovery speed to the patients.

Financial Disclosure:

NONE

Back to Poster listing